Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (3 ops.)
Latest filing published 28 Apr 2026 for Abbott Laboratories. Read the official filing
Filing timeline
BuySaleSally E. Blount
Insider track record
Disclosed buys
2
Disclosed sells
3
Signal history
Closed purchases
Market purchases
2
Positive at T+90
100%
Median T+90
+10.6%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +70.0%Entry US$203.42 · Close at T+365 US$345.77
- +44.5%Entry US$38.38 · Close at T+365 US$55.47
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Sally E. Blount: trading record in brief
Sally E. Blount appears in 19 filings as Director of two companies: Abbott Laboratories (14) and Ulta Beauty, Inc. (5), between May 3, 2016 and April 28, 2026. The year 2019 is the busiest, with 4 filings.
The record mixes purchases and sales. Two purchases total EUR 225,369: EUR 182,373 on November 1, 2016 at Abbott and EUR 42,996 on June 26, 2020 at Ulta Beauty. Three sales weigh EUR 595,783, with a median of EUR 197,914: EUR 297,677 on April 30, 2025 and EUR 197,914 on July 31, 2019 at Abbott, then EUR 100,192 on June 21, 2019 at Ulta Beauty. Purchases make up 40% of the market trades. On top come 14 share grants.
One filing falls in the last twelve months. Filings are published a median of 4 days after the trade, across 19 dated filings.
At Ulta Beauty, Catherine Ann Halligan and Lorna Nagler each reported 2 trades close to this filer's; at Abbott, Brian B. Yoor, Joseph J. Manning and Michael J. Pederson one each.
Companies and markets linked to Sally E. Blount
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
2,286 shares0Common shares without par valueSEC:0001537286-26-000002:0
2,600 shares@ US$129.66100.0% of flowCommon shares without par valueSEC:0001415889-25-011837:0
1,635 shares0Common shares without par valueSEC:0001415889-25-011518:0
1,866 shares0Common shares without par valueSEC:0001415889-24-011790:0
1,816 shares0Common shares without par valueSEC:0001415889-23-007128:0
1,602 shares0Common shares without par valueSEC:0001415889-22-004547:0
1,499 shares0Common shares without par valueSEC:0001415889-21-002156:0
250 shares@ US$193.00100.0% of flowCommon StockSEC:0001567619-20-012634:0
Canonical exit: 24 Sept 2020 (T+90)
1,974 shares0Common shares without par valueSEC:0001179110-20-005180:0
2,500 shares@ US$87.6539.9% of flowCommon shares without par valueSEC:0001104659-19-043751:0
315 shares@ US$359.2870.0% of flowCommon StockSEC:0001567619-19-013888:0
445 shares0Common StockSEC:0001567619-19-012932:0
2,241 shares0Common shares without par valueSEC:0001179110-19-005309:0
587 shares0Common StockSEC:0001140361-18-027715:0
2,945 shares0Common shares without par valueSEC:0001179110-18-006024:0
272 shares0Common StockSEC:0001140361-17-045344:0
3,437 shares0Common shares without par valueSEC:0001179110-17-006404:0
5,100 shares@ US$39.2426.9% of flowCommon shares without par valueSEC:0001179110-16-031089:0
Canonical exit: 30 Jan 2017 (T+90)
3,799 shares0Common shares without par valueSEC:0001179110-16-023671:0
19 of 19 declarations
